Predicted Cardiovascular and Economic Impacts of the Measure Accurately, Act Rapidly, and Partner with Patients Program to Improve Hypertension Control.
Steven P Dehmer, Brent M Egan, Blaine Hardy, Michael V Maciosek, Susan E Sutherland, Stavros Tsipas, Gregory Wozniak
{"title":"Predicted Cardiovascular and Economic Impacts of the Measure Accurately, Act Rapidly, and Partner with Patients Program to Improve Hypertension Control.","authors":"Steven P Dehmer, Brent M Egan, Blaine Hardy, Michael V Maciosek, Susan E Sutherland, Stavros Tsipas, Gregory Wozniak","doi":"10.1016/j.amepre.2025.108132","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study uses microsimulation to estimate 10-year health and economic outcomes that may be achieved by widely adopting the American Medical Association's Measure Accurately, Act Rapidly, and Partner with Patients hypertension (AMA MAP<sup>TM</sup> HTN) quality improvement program.</p><p><strong>Methods: </strong>A microsimulation model was adapted to conduct \"what if\" analyses for adopting the MAP HTN program nationwide and in care delivery systems of varying size. The analysis was conducted in 2020-2024, and the microsimulation model was constructed using various data sources from 1948 to 2019. Modeled outcomes over 10 years included prevalence of systolic blood pressure (SBP) ≥140 mmHg; incidence of cardiovascular disease (CVD) events and CVD-related mortality; averted medical costs by payer in 2021 U.S. dollars; and net costs.</p><p><strong>Results: </strong>For patients with hypertension over 10 years, nationwide adoption of the MAP HTN program was predicted to improve mean BP control by 4.3% and prevent 601 thousand CVD events and 120 thousand CVD deaths. Most of the estimated $17.9 billion in averted disease costs were observed in patients with Medicare. Total costs associated with implementing the MAP HTN program totaled $12.6 billion, resulting in a predicted $5.3 billion in net savings to the health care sector over 10 years. Small and large care delivery organizations could economically benefit from implementing the MAP HTN program at varying levels (5-50%) of shared cost savings from payers.</p><p><strong>Conclusions: </strong>There is promise for quality improvement programs targeting BP management, but more research is needed to affirm the assumptions and findings of this analysis.</p>","PeriodicalId":50805,"journal":{"name":"American Journal of Preventive Medicine","volume":" ","pages":"108132"},"PeriodicalIF":4.5000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Preventive Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amepre.2025.108132","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study uses microsimulation to estimate 10-year health and economic outcomes that may be achieved by widely adopting the American Medical Association's Measure Accurately, Act Rapidly, and Partner with Patients hypertension (AMA MAPTM HTN) quality improvement program.
Methods: A microsimulation model was adapted to conduct "what if" analyses for adopting the MAP HTN program nationwide and in care delivery systems of varying size. The analysis was conducted in 2020-2024, and the microsimulation model was constructed using various data sources from 1948 to 2019. Modeled outcomes over 10 years included prevalence of systolic blood pressure (SBP) ≥140 mmHg; incidence of cardiovascular disease (CVD) events and CVD-related mortality; averted medical costs by payer in 2021 U.S. dollars; and net costs.
Results: For patients with hypertension over 10 years, nationwide adoption of the MAP HTN program was predicted to improve mean BP control by 4.3% and prevent 601 thousand CVD events and 120 thousand CVD deaths. Most of the estimated $17.9 billion in averted disease costs were observed in patients with Medicare. Total costs associated with implementing the MAP HTN program totaled $12.6 billion, resulting in a predicted $5.3 billion in net savings to the health care sector over 10 years. Small and large care delivery organizations could economically benefit from implementing the MAP HTN program at varying levels (5-50%) of shared cost savings from payers.
Conclusions: There is promise for quality improvement programs targeting BP management, but more research is needed to affirm the assumptions and findings of this analysis.
期刊介绍:
The American Journal of Preventive Medicine is the official journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health.
Of particular emphasis are papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women''s health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and substance use disorders. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. Papers on health services research pertinent to prevention and public health are also published. The journal also publishes official policy statements from the two co-sponsoring organizations, review articles, media reviews, and editorials. Finally, the journal periodically publishes supplements and special theme issues devoted to areas of current interest to the prevention community.